MicroRNA-mediated networks underlie immune response regulation in papillary thyroid carcinoma

Scientific Reports

Volumn 4, Issue , 2015, Pages

  Huang, Chen Tsung ^a   Oyang, Yen Jen ^a   Huang, Hsuan Cheng ^b   Juan, Hsueh Fen ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; TUMOR MARKER; TUMOR PROTEIN;

ADULT; BIOSYNTHESIS; CARCINOMA; CELLULAR IMMUNITY; DNA MICROARRAY; FEMALE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PATHOLOGY; THYROID TUMOR;

ADULT; BIOMARKERS, TUMOR; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; IMMUNITY, CELLULAR; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; THYROID NEOPLASMS;

EID: 84925985368     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06495     Document Type: Article

References (60)

1. Kondo, T., Ezzat, S.&Asa, S. L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer 6, 292-306, doi:10.1038/nrc1836 (2006).
2. Xing, M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat. Rev. Cancer 13, 184-199, doi:10.1038/nrc3431 (2013).
3. Schneider, D. F. & Chen, H. New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J. Clin. 63, 374-394, doi:10.3322/caac.21195 (2013).
4. Kazakov, V. S., Demidchik, E. P. & Astakhova, L. N. Thyroid-Cancer after Chernobyl. Nature 359, 21-21, doi:Doi 10.1038/359021a0 (1992).
5. Williams, D. Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat. Rev. Cancer 2, 543-549, doi:10.1038/nrc845 (2002).
6. Xing, M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 12, 245-262, doi:Doi 10.1677/Erc.1.0978 (2005).
7. Lemoine, N. R. et al. High-Frequency of Ras Oncogene Activation in All Stages of Human Thyroid Tumorigenesis. Oncogene 4, 159-164 (1989).
8. Santoro, M., Melillo, R. M. & Fusco, A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur. J. Endocrinol. 155, 645-653, doi:10.1530/eje.1.02289 (2006).
9. Rabes, H. M. et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: Biological, phenotypic, and clinical implications. Clin. Cancer. Res. 6, 1093-1103 (2000).
10. Liu, Z. et al. IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer. Clin. Cancer. Res. 16, 6009-6018, doi:Doi 10.1158/1078-0432.Ccr-10-1627 (2010).
11. Hou, P., Liu, D. X. & Xing, M. Z. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr. Relat. Cancer 18, 687-697, doi:Doi 10.1530/Erc-11-0212 (2011).
12. Lee, R. C., Feinbaum, R. L. & Ambros, V. The C-Elegans Heterochronic Gene Lin-4 Encodes Small Rnas with Antisense Complementarity to Lin-14. Cell 75, 843-854, doi:Doi 10.1016/0092-8674(93)90529-Y (1993).
13. Wightman, B., Ha, I. & Ruvkun, G. Posttranscriptional Regulation of the Heterochronic Gene Lin-14 by Lin-4 Mediates Temporal Pattern-Formation in C-Elegans. Cell 75, 855-862, doi:Doi 10.1016/0092-8674(93)90530-4 (1993).
14. Bartel, D. P. MicroRNAs: Target Recognition and Regulatory Functions. Cell 136, 215-233, doi:DOI 10.1016/j.cell.2009.01.002 (2009).
15. Ameres, S. L. & Zamore, P. D. Diversifying microRNA sequence and function. Nat. Rev. Mol. Cell Biol. 14, 475-488, doi:10.1038/nrm3611 (2013).
16. Ling, H., Fabbri, M. & Calin, G. A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 12, 847-865, doi:10.1038/nrd4140 (2013).
17. Calin, G. A. & Croce, C. M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6, 857-866, doi:10.1038/nrc1997 (2006).
18. He, L. et al. A microRNA component of the p53 tumour suppressor network. Nature 447, 1130-1134, doi:10.1038/nature05939 (2007).
19. Johnson, S. M. et al. RAS is regulated by the let-7 MicroRNA family. Cell 120, 635-647, doi:DOI 10.1016/j.cell.2005.01.014 (2005).
20. Vasudevan, S., Tong, Y. C. & Steitz, J. A. Switching from repression to activation: MicroRNAs can up-regulate translation. Science 318, 1931-1934, doi:DOI 10.1126/science.1149460 (2007).
21. Tay, Y., Rinn, J. & Pandolfi, P. P. The multilayered complexity of ceRNA crosstalk and competition. Nature 505, 344-352, doi:10.1038/nature12986 (2014).
22. Poliseno, L. et al.Acoding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465, 1033-1038, doi:10.1038/nature09144 (2010).
23. Fabbri, M. et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. U. S. A. 109, E2110-2116, doi:10.1073/pnas.1209414109 (2012).
24. Lehmann, S. M. et al. An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat. Neurosci. 15, 827-835, doi:10.1038/nn.3113 (2012).
25. Dvinge, H. et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 497, 378-382, doi:10.1038/nature12108 (2013).
26. He, H. et al. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl. Acad. Sci. U. S. A. 102, 19075-19080, doi:10.1073/pnas.0509603102 (2005).
27. Pallante, P. et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr. Relat. Cancer 13, 497-508, doi:10.1677/erc.1.01209 (2006).
28. Chou, C. K. et al. Prognostic Implications of miR-146b Expression and Its Functional Role in Papillary Thyroid Carcinoma. J. Clin. Endocrinol. Metab. 98, E196-E205, doi:10.1210/jc.2012-2666 (2013).
29. Menon, M. P. & Khan, A. Micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications. J. Clin. Pathol. 62, 978-985, doi:10.1136/jcp.2008.063909 (2009).
30. Zaman, N. et al. Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets. Cell Rep 5, 216-223, doi:10.1016/j.celrep.2013.08.028 (2013).
31. Broad Institute TCGA Genome Data Analysis Center (2014): SNP6 Copy number analysis (GISTIC2). Broad Institute of MIT and Harvard. doi:10.7908/C1M61HZV.
32. Grimson, A. et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 27, 91-105, doi:10.1016/j.molcel.2007.06.017 (2007).
33. Betel, D., Koppal, A., Agius, P., Sander, C.&Leslie, C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 11, R90, doi:10.1186/gb-2010-11-8-r90 (2010).
34. Geraldo, M. V., Yamashita, A. S. & Kimura, E. T. MicroRNA miR-146b-5p regulates signal transduction of TGF-beta by repressing SMAD4 in thyroid cancer. Oncogene 31, 1910-1922, doi:10.1038/onc.2011.381 (2012).
35. Lee, D. Y. et al. Expression of versican 39-untranslated region modulates endogenous microRNA functions. PLoS One 5, e13599, doi:10.1371/journal.pone.0013599 (2010).
36. Rutnam, Z. J.&Yang, B. B. The non-coding 3 9 UTRof CD44 induces metastasis by regulating extracellular matrix functions. J. Cell Sci. 125, 2075-2085, doi:10.1242/jcs100818 (2012).
37. Fang, L. et al. Versican 3′-untranslated region (3′-UTR) functions as a ceRNA in inducing the development of hepatocellular carcinoma by regulating miRNA activity. FASEB J. 27, 907-919, doi:10.1096/fj.12-220905 (2013).
38. Gasbarri, A. et al. Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto's thyroiditis. Br. J. Cancer 91, 1096-1104, doi:10.1038/sj.bjc.6602097 (2004).
39. Prasad, M. L., Huang, Y., Pellegata, N. S., de la Chapelle, A. & Kloos, R. T. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. Histopathology 45, 39-46, doi:10.1111/j.1365-2559.2004.01876.x (2004).
40. Boutzios, G. et al. Higher incidence of tall cell variant of papillary thyroid carcinoma in graves' disease. Thyroid 24, 347-354, doi:10.1089/thy.2013.0133 (2014).
41. Ou, W. B., Zhu, M. J., Demetri, G. D., Fletcher, C. D. & Fletcher, J. A. Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors. Oncogene 27, 5624-5634, doi:10.1038/onc.2008.177 (2008).
42. Wu, Z. et al. HLA-DMB expression by thyrocytes: indication of the antigen-processing and possible presenting capability of thyroid cells. Clin. Exp. Immunol. 116, 62-69 (1999).
43. Rahat, M. A., Chernichovski, I. & Lahat, N. Increased binding of IFN regulating factor 1 mediates the synergistic induction of CIITA by IFN-gamma and tumor necrosis factor-alpha in human thyroid carcinoma cells. Int. Immunol. 13, 1423-1432 (2001).
44. Shah, R. et al. Intense expression of the b7-2 antigen presentation coactivator is an unfavorable prognostic indicator for differentiated thyroid carcinoma of children and adolescents. J. Clin. Endocrinol. Metab. 87, 4391-4397, doi:10.1210/jc.2002-011262 (2002).
45. Lin, H. Y. et al. Potentiation by thyroid hormone of human IFN-gamma-induced HLA-DR expression. J. Immunol. 161, 843-849 (1998).
46. Qiu, Y. et al. Immunoglobulin G expression and its colocalization with complement proteins in papillary thyroid cancer. Mod. Pathol. 25, 36-45, doi:10.1038/modpathol.2011.139 (2012).
47. Takaoka, A. et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448, 501-505, doi:10.1038/nature06013 (2007).
48. Hebert, C., Norris, K., Scheper, M. A., Nikitakis, N. & Sauk, J. J. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol. Cancer 6, 5, doi:10.1186/1476-4598-6-5 (2007).
49. Alajez, N. M. et al. Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis. 1, e85, doi:10.1038/cddis.2010.64 (2010).
50. Jacobson, E. M. & Tomer, Y. The genetic basis of thyroid autoimmunity. Thyroid 17, 949-961, doi:10.1089/thy.2007.0153 (2007).
51. Cerutti, J. M. et al. Molecular profiling of matched samples identifies biomarkers of papillary thyroid carcinoma lymph node metastasis. Cancer Res. 67, 7885-7892, doi:10.1158/0008-5472.CAN-06-4771 (2007).
52. Puxeddu, E. et al. RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Endocr. Relat. Cancer 12, 319-334, doi:10.1677/erc.1.00947 (2005).
53. Barbosa, M. D. et al. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature 382, 262-265, doi:10.1038/382262a0 (1996).
54. Faigle, W. et al. Deficient peptide loading and MHC class II endosomal sorting in a human genetic immunodeficiency disease: the Chediak-Higashi syndrome. J. Cell Biol. 141, 1121-1134 (1998).
55. Giles, K. M., Brown, R. A., Epis, M. R., Kalinowski, F. C. & Leedman, P. J. miRNA-7-5p inhibits melanoma cell migration and invasion. Biochem. Biophys. Res. Commun. 430, 706-710, doi:10.1016/j.bbrc.2012.11.086 (2013).
56. Sarver, A. L., Li, L. & Subramanian, S. MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res. 70, 9570-9580, doi:10.1158/0008-5472.CAN-10-2074 (2010).
57. Arora, S. et al. MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int. J. Cancer 129, 2621-2631, doi:10.1002/ijc.25939 (2011).
58. Moskwa, P. et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol. Cell 41, 210-220, doi:10.1016/j.molcel.2010.12.005 (2011).
59. Liu, X. et al. MicroRNA-148/152 impair innate response and antigen presentation of TLR-triggered dendritic cells by targeting CaMKIIalpha. J. Immunol. 185, 7244-7251, doi:10.4049/jimmunol.1001573 (2010).
60. Kozomara, A. & Griffiths-Jones, S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39, D152-157, doi:10.1093/nar/gkq1027 (2011).